ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC

Another successful antibody-drug conjugate (ADC) looks set to roll off Daiichi Sankyo’s production line. After teasing early data on the B7-H3-directed candidate one year ago, the Japanese drugmaker has now linked DS-7300 to a 58% response rate in small cell lung cancer (SCLC) and responses in other tumors.